Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study

[1]  A. Hagemeijer,et al.  High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Konopleva,et al.  Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients , 2012, Cancer.

[3]  E. Estey,et al.  Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia , 2011, British journal of haematology.

[4]  Y. Kwong,et al.  Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia , 2011, Annals of Hematology.

[5]  Augustin Ferrant,et al.  Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.

[6]  J. Fay,et al.  Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. , 2011, The oncologist.

[7]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Hagemeijer,et al.  Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial , 2010, Haematologica.

[9]  R. Hills,et al.  European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Gabrilove,et al.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Z. Estrov,et al.  Clofarabine combinations as acute myeloid leukemia salvage therapy , 2008, Cancer.

[12]  Z. Estrov,et al.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. , 2008, Blood.

[13]  Z. Estrov,et al.  Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. , 2006, Blood.

[14]  H. Kantarjian,et al.  The role of clofarabine in hematologic and solid malignancies—Development of a next‐generation nucleoside analog , 2005, Cancer.

[15]  V. Gandhi,et al.  Biochemical modulation of cytarabine triphosphate by clofarabine , 2005, Cancer Chemotherapy and Pharmacology.

[16]  E. Estey,et al.  Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. , 2005, Blood.

[17]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kantarjian,et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.

[19]  F. Khuri,et al.  Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[21]  M. Gordon.  Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10 , 2010 .